CAV1 and cancer: In advanced-stage cancers, Cav1 promotes EMT by upregulating mesenchymal markers such as vimentin and N-cadherin while reducing epithelial markers like E-cadherin (Liang et al., 2014; Zhang K. et al., 2016).